These vaccine candidates combine the flu vaccine with the Novavax COVID-19 vaccine, offering a potential single shot to address both diseases.
The designation was granted to expedite the development of vaccines that could help reduce the health burdens of flu and COVID-19, especially for groups that are at higher risk of severe outcomes such as prolonged hospital stays and long-term complications.
The first combination candidate combines Fluzone High-Dose, a high-dose flu vaccine, with Novavax’s COVID-19 vaccine. The second candidate uses Flublok, a recombinant flu vaccine paired with the same Novavax COVID-19 vaccine.
Both flu vaccines have been shown to be more effective than standard-dose flu vaccines in preventing infections and reducing hospitalizations in older adults. The Novavax COVID-19 vaccine has also demonstrated good safety and efficacy profiles in previous clinical trials, according to the release.
Sanofi, which is developing the vaccines, has launched phase ½ clinical trials to evaluate the safety and immune responses to the combination shots. The trials aim to assess whether combining these vaccines can maintain their efficacy while simplifying vaccination schedules, potentially improving uptake among older adults.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
